Using the RASTRUM™ platform, we have developed fully defined patient-derived liver cancer models for high throughput drug development in environments more accurately recreating the unique liver microenvironment than traditional organoid culture methods.

The RASTRUM™ platform has revolutionized our ability to create highly organized and reproducible 3D breast and ovarian cancer models in a stable and tuneable tumour microenvironment that is not possible in 2D. Combined with standard imaging platforms, this technology will certainly advance our ability to better understand, model and treat these diseases.

The RASTRUM™ platform has enabled us to recreate humanized beating cardiac 3D organoids from induced pluripotent stem cells (iPSC). The organoids can be printed at the iPSC stage and differentiated in the plugs, allowing us to study cells across their development. The scale enabled by the RASTRUM™ platform means we can test for the interaction of genetics on drug response, identifying patient-specific cardiotoxicity events.

The RASTRUM™ platform has enabled us to recreate humanised endocrine 3D primary breast cancer models, in a physiologically-relevant and defined tumour microenvironment that cannot be achieved using traditional approaches.

The RASTRUM™ bioprinter has allowed us to successfully maintain and expand primary samples of children's cancer in high throughput that have otherwise proved difficult to grow in vitro by recapitulating a physiologically relevant 3D tumour extracellular environment.

The RASTRUM™ platform has allowed us to efficiently and reproducibly generate 3D brain organoids from induced pluripotent stem cells for our research on neurodegenerative disease

Using the RASTRUM™ platform, we have developed fully defined patient-derived liver cancer models for high throughput drug development in environments more accurately recreating the unique liver microenvironment than traditional organoid culture methods.